Long-acting beta2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults and children

Gibson PG, Powell H, Ducharme FM

Published Online:

July 8, 2009

The combination of long acting beta agonist (LABA) with inhaled corticosteroid (ICS) is used frequently in asthma and a benefit from adding LABA to ICS has been described. This review compared reduced dose (mean 60% reduction in inhaled steroid) ICS/LABA combination to either a fixed moderate/high dose ICS or a reduced/tapering ICS dose. In adults with asthma, who use moderate to high maintenance doses of ICS, the addition of LABA has an ICS-sparing effect. LABA permit a reduction of 37% (253 mcg BDP) in subjects on minimum maintenance ICS and up to 60% (300 mcg FP) in subjects on maintenance ICS without deterioration in asthma control.

Abstract (click to read)

Background:

The addition of a long acting beta agonist (LABA) to inhaled corticosteroid (ICS) therapy can improve asthma symptoms and reduce exacerbations. The addition of LABA may also have an ICS-sparing effect and permit a reduction in ICS maintenance dose.

Objectives:

To determine the efficacy of adding LABA to maintenance ICS therapy in reducing the requirement for ICS while maintaining control of chronic asthma.

Search strategy:

We searched the Cochrane Airways Group trials register and reference lists of articles. Date of last search: November 2004

Selection criteria:

Parallel RCTs that compared reduced dose ICS in combination with LABA vs ICS alone in asthmatics requiring daily ICS.

Data collection and analysis:

Trial quality was assessed and data were extracted independently by two reviewers. Study authors were contacted for confirmation. Trials were analysed according to the following ICS dose comparisons: a fixed moderate/high dose or a reduced/tapering dose of the same ICS.

Main results:

19 publications describing 10 trials of adults were included in the review. Studies that compared reduced dose (mean 60% reduction) ICS/LABA combination to a fixed moderate/high dose ICS found no significant difference in severe exacerbations requiring oral corticosteroids (RR 1.0, 95%CI 0.76 to 1.32), withdrawal due to worsening asthma (RR 0.82, 95%CI 0.5 to 1.35) or airway inflammation. There were also significant improvements in FEV1 (change from baseline WMD 0.10, 95%CI 0.07 to 0.12), morning & evening PEF and percent rescue free days with LABA. Two studies provided outcomes for a reduced/tapering ICS dose comparison. More participants receiving the LABA/reduced ICS combination achieved a reduction in ICS dose reaching significance in one study. A significant reduction of 253 mcg BDP was achieved in one study.

Authors' conclusions:

In adults with asthma, using moderate to high maintenance doses of ICS, the addition of LABA has an ICS-sparing effect. The addition of LABA permits more participants on minimum maintenance ICS to reduce ICS. The precise magnitude of the ICS dose reduction requires further study.

This record should be cited as:

Gibson PG, Powell H, Ducharme FM. Long-acting beta2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD005076. DOI: 10.1002/14651858.CD005076.pub2

Assessed as up to date:

July 26, 2005

Find the research

Get full text at The Cochrane Library

Primary Review Group:

Airways Group

Asthma topics:

Treating with Medications > Steroids > Steroid sparing agents

Treating with Medications > Chronic Asthma > Beta-agonists, long-acting

Health topics:

Lungs & airways > Asthma (chronic) > Bronchodilators

Lungs & airways > Asthma (chronic) > Steroid-sparing

Cochrane Summaries^beta

Independent high-quality evidence for health care decision making

Long-acting beta2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults and children

More like this

Copyright © 2012 - The Cochrane Collaboration